Pseudoprogression after advanced first-line endocrine therapy in metastatic breast cancer with bone metastasis: A case report

ABSTRACT: Approximately 75% of patients with advanced breast cancer develop bone metastasis, which significantly affects both the quality of life and the survival rate of patients. Accurate determination of the status of bone metastases is important for developing treatment strategies and the prognosis of the disease. Here, we report the case of a 33-year-old patient with advanced metastatic breast cancer (MBC) and multiple bone metastases, in which advanced first-line endocrine therapy and second-line chemotherapy were both considered unsuccessful according to the efficacy evaluation by conventional imaging. Considering the possibility of bone pseudoprogression, the original endocrine scheme was reapplied, and bone metastases achieved a great response of non-complete response (CR)/non-progressive d

SUBMITTER: Tian A 

PROVIDER: S-EPMC9845761 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature